SURF — Surface Oncology Income Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $65.08m
- $8.82m
- $30.00m
Annual income statement for Surface Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 59.4 | 15.4 | 126 | 2.69 | 30 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Operating Interest Expense / Income | |||||
| Total Operating Expenses | 66 | 70.1 | 66.8 | 78.7 | 91.9 |
| Operating Profit | -6.6 | -54.8 | 59.3 | -76 | -61.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.6 | -54.8 | 59.3 | -78.5 | -63.6 |
| Net Income After Taxes | -6.6 | -54.8 | 59.3 | -78.5 | -63.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.6 | -54.8 | 59.3 | -78.5 | -63.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.61 | -54.8 | 59.3 | -78.5 | -63.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.33 | -1.97 | 1.56 | -1.77 | -1.14 |